Pardale-V™ Oral Tablets

Species: Dogs
Therapeutic indication:Pharmaceuticals: Neurological preparations: Analgesics
Active ingredient: Codeine Phosphate, Paracetamol
Product: Pardale-V™ Oral Tablets
Product index: Pardale-V Oral Tablets

Qualitative and quantitative composition

Each tablet contains: Active substances:

Paracetamol 400 mg

Codeine phosphate hemihydrate 9 mg

Pharmaceutical form

Tablet. White, flat tablets with a bevelled edge and a break-line.

Clinical particulars

Target species

Dogs.

Indications for use

For analgesic therapy in dogs only. The product is indicated for acute pain of traumatic origin, as a complementary treatment in pain associated with other conditions and post operative analgesia.

Contraindications

Do not exceed stated dose or duration of treatment.

Do not administer other NSAIDs concurrently or within 24 hours of each other.

Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where

there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.

Do not use this product for cats.

Special warnings for each target species

Seek veterinary advice if the treated condition does not improve or worsens during treatment, or if any side effects or adverse reactions are experienced.

NSAIDs can cause inhibition of phagocytosis and hence, in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.

Special precautions for use in animals

Use in animals less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require a reduced dosage and careful clinical management.

Avoid use in dehydrated, hypovolaemic or hypotensive animals, as there is a potential risk of increased renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Wash hands after use.

Adverse reactions

Occasional constipation may occur due to codeine content.

Use during pregnancy and lactation

There are no known contraindications for use during pregnancy.

Interactions

Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.

Concurrent administration of potentially nephrotoxic drugs should be avoided.

Amounts to be administered and administration route

For oral administration. 1 tablet/12 kg body weight every 8 hours.

Small dogs (up to 6 kg body weight): ½ tablet every 8 hours.

Medium dogs (6-18 kg body weight): ½-1½ tablets every 8 hours.

Large dogs (18-42 kg body weight): 1½-3½ tablets every 8 hours.

Treat for a maximum of 5 days.

Overdose

Immediately seek the advice of a veterinary surgeon, and show him/her the product literature.

Carry out lavage and treat with intravenous injection of acetylcysteine (200 mg/ml) at a rate of 140 mg/kg every 6 hours for 7 treatments. Ascorbic acid (30 mg/kg) should also be given orally with each dose of acetylcysteine.

If necessary instigate fluid therapy using Ringers or bicarbonate solution.

Treat for codeine overdose with injection of naloxone (1.0 mg/kg) repeated as necessary.

Provide oxygen support.

Pharmacological particulars

Pharmacotherapeutic group: Analgesics, other analgesics and antipyretics, anilides.

ATCvet code: QN02BE71

Pharmacodynamic properties

Paracetamol is a para aminophenyl derivative with analgesic properties.

Codeine is an opioid analgesic.

Pharmacokinetic properties

Both paracetamol and codeine are readily absorbed from the gastrointestinal tract. They are metabolised in the liver (codeine to morphine and narcodeine). Codeine and its metabolites are excreted almost entirely by the kidney, whilst less than 5 % of paracetamol is excreted unchanged.

Pharmaceutical particulars

Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.

Special precautions for storage

Do not store above 25°C.

Immediate packaging

Polypropylene container with a low density polyethylene tamper evident lid, containing 100 or 500 plain white, flat tablets with bevelled edges and a break line on one side and DPL on the other.

Disposal

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

Marketing Authorisation Holder (if different from distributor)

Dechra Limited, Snaygill Industrial Estate, Keighley Road, Skipton, North Yorkshire, BD23 2RW, United Kingdom.

Marketing Authorisation Number

Vm 10434/4034

Significant changes

Date of the first authorisation or date of renewal

10 October 2007

Date of revision of the text

January 2016

Any other information

For animal treatment only. Keep out of the sight and reach of children.

Legal category

Legal category:NFA-VPS

GTIN

GTIN description: Pardale-V Oral Tablets 100 tablets:
GTIN:05055031400119
GTIN description: Pardale-V Oral Tablets 500 tablets:
GTIN:05055031400102

Dechra Veterinary Products
Telephone:01939 211200
Website:www.dechra.co.uk
Email:info.uk@dechra.com